Heidelberg Pharma Announces Participation at Various Conferences

DGAP-News: Heidelberg Pharma AG

/ Key word(s): Conference

10.09.2020 / 07:56

The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Heidelberg Pharma Announces Participation at Various Conferences

Ladenburg, Germany, 10 September 2020 – Heidelberg Pharma AG (FSE: HPHA) today announced that they will participate at the following events. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology, and to advance the biological mode of action of the toxin as a novel therapeutic principle.

H.C. Wainwright 22nd Annual Global Investment Conference (virtual format)
Date: 14th – 16th September 2020

Details of the presentation
ATACs: a unique new mode of action to fight cancer
Date: 16th September 2020 at 10:00 am EDT / 04:00 pm CEST
Presenter: Dr Jan Schmidt-Brand, Chief Executive Officer and Chief Financial Officer
Access to the presentation: https://wsw.com/webcast/hcw7/hpha.f/1773389

International HealthTech Innovation Days (mixed format)
Date: 5th – 6th October 2020
Venue: The Peninsula Paris, Paris and virtual

Dr. Jan Schmidt-Brand will participate as a speaker on 5th October 2020 at 05:30 pm in the podium discussion “Opportunities and challenges for Innovative Healthtech companies in Europe”.

About Heidelberg Pharma’s proprietary ATAC technology
Antibody Drug Conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.

About Heidelberg Pharma
Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies. The proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs as well as in third-party collaborations. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma.

Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com.

Contact
Heidelberg Pharma AG
Corporate Communications
Sylvia Wimmer
Tel.: +49 89 41 31 38-29
E-Mail: investors[at]hdpharma.com
Gregor-Mendel-Str. 22, 68526 Ladenburg
IR/PR support
MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49 89 210 228-40
Mobil: +49 160 9360 3022
E-Mail: katja.arnold[at]mc-services.eu
 

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.


10.09.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Heidelberg Pharma AG
Gregor-Mendel-Str. 22
68526 Ladenburg
Germany
Phone: +49 (0)89 41 31 38 – 0
Fax: +49 (0)89 41 31 38 – 99
E-mail: investors@hdpharma.com
Internet: www.heidelberg-pharma.com
ISIN: DE000A11QVV0
WKN: A11QVV
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1129635

 
End of News DGAP News Service

show this